Скачать или смотреть Humacyte's Bioengineered Vessel: A Potential Game-Changer for Hemodialysis Access

In a groundbreaking study presented at the American Society of Nephrology Kidney Week 2025, researchers explored the long-term outcomes of Humacyte's Acellular Tissue Engineered Vessel (ATEV) as an alternative to the standard autologous arteriovenous fistula (AVF) for hemodialysis access.
The phase 3 trial, CLN-PRO-V007, randomly assigned 242 patients to either the ATEV or AVF group. Results showed that ATEV provided a numerically longer duration of access use and a higher proportion of patients maintained secondary patency at 12 months compared to AVF.
Additionally, ATEV demonstrated comparable safety relative to AVFs, with low rates of infections and adverse events. These findings suggest that ATEV could be a durable and clinically viable option, especially for patients at risk of AVF maturation failure.
Join us as we delve into the details of this exciting research and its potential impact on hemodialysis access.